SeqOnce Biosciences

SeqOnce bringing a wrecking ball to upend, disrupt and revolutionize the $34 billion genomics market

Print
Follow Claim My Business
Security Type
SAFE
Min Investment
$100
Offering Date
February 18, 2025
Expected Close Date
April 30, 2025
No. Investors
57
Website
seqonce.com

Company Description

SeqOnce is an innovative, DeepTech company with expertise in qPCR, NGS, and novel tech development

Perks

Invest
$1,000
Receive
Pack of SeqOnce Stickers, including one of the Rhino

Invest
$2,500
Receive
An exclusive investors-only coffee mug, with the pic of the Rhino,
plus all tiers above

Invest
$7,500
Receive
Name on the Investor Surfboard that is the lobby at the company HQ,
plus all tiers above.

Invest
$15,000
Receive
A virtual call and tour of our HQ, with member of Sr. Staff
plus all tiers above

Key Deal Facts

Generated over $45M revenue to date - Run rate of $100K to $250K/month
New Game-Changing Technology: Creating massive future valuation potential
Launched 9 products, Developed 2 new novel technologies
Diversified: Products and Markets - Including DTC (Direct to Consumer)
Patent protected: Patent coverage across the US, EU, and China
Minimal outside investment: Less than $1M raised total, clean cap table
Investors include: Wavemaker 360 Health, a top-tier venture capital firm

Management Team / Advisory Board Bios

Chris Angermayer, MBA
CEO - Founder
Chris is a former finance industry executive turned genomics entrepreneur, and founder, with over 20 years of experience in leadership roles.

Joseph Dunham, PhD
CSO - Founder
Joseph is an expert in molecular biology and genomics and is an inventor that holds multiple biotechnology patents. He is a founder, and develops and leads the scientific initiatives.

Tim Harkins, PhD
COO
Tim is an industry expert in diagnostics and genomics with 25 years in biotech. Parabricks (exit), Life Tech, Roche, Swift (exit) Amersham, NVIDIA, and Applied Biosystems.

Alan Horsager, PhD
CBO - Consulting
Alan is an biotech entrepreneur leading companies from early discovery to commercialization and acquisition. He recently founded Concept Bio, a venture studio dedicated to nurturing early-stage biotech companies.

Cyrus Arman, PhD, MBA
Sr Strategist - Consulting
Cyrus is a Biotech entrepreneur. He recently founded Concept Bio, a venture studio dedicated to nurturing early-stage biotech companies.

Martin Pieprzyk
Sr Commercial Advisor

Scott Fraser, PhD
Scientific Advisor

Scott Tighe
Scientific Advisor
Amount Raised : $114,891
Reveal the Score by Voting
_
0
Business Idea
Business Traction
Management Team
Valuation

Security Description

A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments